TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
Brief Summary: To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.


Options:
A: Arm Label: milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg
D: Arm Label: CBT and milnacipran; Type: EXPERIMENTAL; Interventions: Other: CBT and milnacipran | Arm Label: CBT and placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: CBT with a placebo | Arm Label: Educational with milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Educational with milnacipran | Intervention Type: OTHER; Name: CBT and milnacipran; Assigned to Arm(s): CBT and milnacipran | Intervention Type: BEHAVIORAL; Name: CBT with a placebo; Assigned to Arm(s): CBT and placebo | Intervention Type: DRUG; Name: Educational with milnacipran; Assigned to Arm(s): Educational with milnacipran

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
Brief Summary: To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.


Options:
A: Arm Label: Pregabalin; Type: ACTIVE_COMPARATOR; Interventions: Drug: pregabalin | Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride | Arm Label: Gabapentin + Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine hydrochloride, Drug: gabapentin | Intervention Type: DRUG; Name: duloxetine hydrochloride; Assigned to Arm(s): Duloxetine, Gabapentin + Duloxetine | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: gabapentin; Assigned to Arm(s): Gabapentin + Duloxetine
B: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Placebo | Arm Label: Pregabalin+Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin, Drug: Placebo | Arm Label: Duloxetine + Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine, Drug: Pregabalin, Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Duloxetine, Duloxetine + Pregabalin, Pregabalin, Pregabalin+Duloxetine
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Dose Response Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome
Brief Summary: To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.


Options:
A: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 fatty acid | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3 fatty acid; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
B: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: All patients; Type: N/A; Interventions: N/A
D: Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Comparison of LY686017, Paroxetine, and Placebo in the Treatment of Social Anxiety Disorder
Brief Summary: This study is a Phase 2 trial to test the efficacy of LY686017 in the treatment of Social Anxiety Disorder.


Options:
A: Arm Label: Vilazodone; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: LY686017; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Arm Label: PH94B intranasal spray; Type: EXPERIMENTAL; Interventions: Drug: PH94B intranasal spray | Arm Label: Placebo intranasal spray; Type: PLACEBO_COMPARATOR; Interventions: Drug: PH94B intranasal spray | Intervention Type: DRUG; Name: PH94B intranasal spray; Assigned to Arm(s): PH94B intranasal spray, Placebo intranasal spray
D: Intervention Type: DRUG; Name: quetiapine; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Multicenter Study of Immediate Postoperative Instillation of Gemcitabine in Patients With Superficial Transitional Cell Carcinoma of the Bladder
Brief Summary: A randomized, double-blind, placebo-controlled Phase 3 multicenter study to assess the efficacy and safety of intravesical instillation of gemcitabine versus placebo immediately after transurethral resection of the bladder tumor.


Options:
A: Arm Label: Cysview arm; Type: EXPERIMENTAL; Interventions: Drug: Hexaminolevulinate hydrochloride, Device: KARL STORZ D-Light C PDD Flexible Videoscope System | Intervention Type: DRUG; Name: Hexaminolevulinate hydrochloride; Assigned to Arm(s): Cysview arm | Intervention Type: DEVICE; Name: KARL STORZ D-Light C PDD Flexible Videoscope System; Assigned to Arm(s): Cysview arm
B: Arm Label: Hexvix cystoscopy group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hexvix | Arm Label: White light; Type: OTHER; Interventions: Other: Standard white light cystoscopy | Intervention Type: DRUG; Name: Hexvix; Assigned to Arm(s): Hexvix cystoscopy group | Intervention Type: OTHER; Name: Standard white light cystoscopy; Assigned to Arm(s): White light
C: Arm Label: Mitomycin C; Type: EXPERIMENTAL; Interventions: Drug: Mitomycin C | Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Mitomycin C; Assigned to Arm(s): Mitomycin C | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Optimization of Growth Hormone Treatment in Short Children Born Small for Gestational Age Based on a Growth Prediction Model-The OPTIMA Trial
Brief Summary: Comparison of 2 different doses of human growth hormone treatment on change in height after 1 and 2 years of treatment.


Options:
A: Arm Label: "Individual" or "standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: rFSH drug dose | Arm Label: "Standard" rFSH dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: "Standard" rFSH dose | Intervention Type: DRUG; Name: rFSH drug dose; Assigned to Arm(s): "Individual" or "standard" rFSH dose | Intervention Type: DRUG; Name: "Standard" rFSH dose; Assigned to Arm(s): "Standard" rFSH dose
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: Computer-Assisted Decision Support | Intervention Type: PROCEDURE; Name: Computer-Assisted Decision Support; Assigned to Arm(s): 2
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: Algorithm for phenprocoumon | Arm Label: B; Type: EXPERIMENTAL; Interventions: Other: algorithm for phenprocoumon | Arm Label: C; Type: ACTIVE_COMPARATOR; Interventions: Drug: Phenprocoumon | Intervention Type: OTHER; Name: Algorithm for phenprocoumon; Assigned to Arm(s): A | Intervention Type: OTHER; Name: algorithm for phenprocoumon; Assigned to Arm(s): B | Intervention Type: DRUG; Name: Phenprocoumon; Assigned to Arm(s): C
D: Intervention Type: DRUG; Name: somatropin; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy
Brief Summary: This trial compares two chemotherapy agents for the treatment of recurrent ovarian, fallopian or primary peritoneal cancer in patients that have received and are no longer responding to Platinum based treatment. The purpose of this trial is to compare progression free survival between gemcitabine and liposomal doxorubicin. Progression free survival (PFS) is defined as the period from study entry until disease progression


Options:
A: Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): N/A
C: Arm Label: Olaparib tablets p.o. 300mg twice daily; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets p.o. twice daily; Type: PLACEBO_COMPARATOR; Interventions: Drug: Olaparib 300mg tablets | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib tablets p.o. 300mg twice daily, Placebo tablets p.o. twice daily
D: Arm Label: A: Paclitaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel | Arm Label: B: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: C: Olaparib and Cediranib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib, Drug: Cediranib | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): B: Olaparib, C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Cediranib; Assigned to Arm(s): C: Olaparib and Cediranib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): A: Paclitaxel

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Ten-Week, Randomized, Double-Blind Study Evaluating the Efficacy of Duloxetine 60mg Once Daily Versus Placebo in Outpatients With Major Depressive Disorder and Pain
Brief Summary: To determine the efficacy of Duloxetine vs. placebo on pain as determined by change in the Brief Pain Inventory (BPI) from baseline over 8 weeks of treatment


Options:
A: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine
B: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Duloxetine Hydrochloride; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Duloxetine; Type: EXPERIMENTAL; Interventions: Drug: Duloxetine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): Duloxetine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Switching to Duloxetine From Other Antidepressants: A Regional Multicentre Trial Comparing Two Switching Techniques
Brief Summary: A multicentre, randomised, open label study of out-patients with major depression who have failed to respond adequately to antidepressant treatment for their current episode of depression. The study compares outcomes associated with two methods of switching from current antidepressant to duloxetine


Options:
A: Arm Label: Vortioxetine 10 mg or 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Vortioxetine (Lu AA21004) | Arm Label: Agomelatine 25 mg or 50 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Agomelatine | Intervention Type: DRUG; Name: Vortioxetine (Lu AA21004); Assigned to Arm(s): Vortioxetine 10 mg or 20 mg | Intervention Type: DRUG; Name: Agomelatine; Assigned to Arm(s): Agomelatine 25 mg or 50 mg
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: lamotrigine, Drug: paroxetine | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo, Drug: paroxetine | Intervention Type: DRUG; Name: lamotrigine; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Brief Summary: Gemcitabine has been shown to be highly effective and well tolerated in the first and second line therapy, as a single agent or in combination therapy for treatment of metastatic transitional cell carcinoma. On the basis of Gemcitabine clinical activity and good tolerability this drug has been recently tested in intravesical therapy. we consider Gemcitabine as a good therapy candidate for patient with intermediate risk superficial bladder cancer. Based on the phase I/II clinical trials w are going to explore the efficacy and tolerability of Gemcitabine in this setting, and compare it to Mitomycin C which is widely used in this group of patients.


Options:
A: Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: mitomycin C; Assigned to Arm(s): N/A
B: Arm Label: Cohort 1: Erdafitinib; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Arm Label: Cohort 1: Investigators Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Investigator Choice (Gemcitabine), Drug: Investigator Choice (Mitomycin C) | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Intervention Type: DRUG; Name: Erdafitinib; Assigned to Arm(s): Cohort 1: Erdafitinib, Cohort 2, Cohort 3 | Intervention Type: DRUG; Name: Investigator Choice (Gemcitabine); Assigned to Arm(s): Cohort 1: Investigators Choice | Intervention Type: DRUG; Name: Investigator Choice (Mitomycin C); Assigned to Arm(s): Cohort 1: Investigators Choice
C: Arm Label: Cysview arm; Type: EXPERIMENTAL; Interventions: Drug: Hexaminolevulinate hydrochloride, Device: KARL STORZ D-Light C PDD Flexible Videoscope System | Intervention Type: DRUG; Name: Hexaminolevulinate hydrochloride; Assigned to Arm(s): Cysview arm | Intervention Type: DEVICE; Name: KARL STORZ D-Light C PDD Flexible Videoscope System; Assigned to Arm(s): Cysview arm
D: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Study to Evaluate the Effectiveness of Flumist (Influenza Vaccine, Live Intranasal) Vaccination in a School-Based Intervention Program
Brief Summary: To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.


Options:
A: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: EXPERIMENTAL; Interventions: Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: FluMist | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 1
D: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IV Study to Evaluate the Effectiveness of Flumist (Influenza Vaccine, Live Intranasal) Vaccination in a School-Based Intervention Program
Brief Summary: To measure the effectiveness of influenza vaccination in school children by comparing, between target(i.e., children are offered FluMist) and control (i.e., children are not offered FluMist) school families.


Options:
A: Arm Label: Q/LAIV (MEDI3250); Type: EXPERIMENTAL; Interventions: Biological: Q/LAIV (MEDI3250) | Arm Label: FluMist/B/Yamagata; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist/B/Yamagata | Arm Label: FluMist/B/Victoria; Type: ACTIVE_COMPARATOR; Interventions: Biological: FluMist/B/Victoria | Intervention Type: BIOLOGICAL; Name: Q/LAIV (MEDI3250); Assigned to Arm(s): Q/LAIV (MEDI3250) | Intervention Type: BIOLOGICAL; Name: FluMist/B/Yamagata; Assigned to Arm(s): FluMist/B/Yamagata | Intervention Type: BIOLOGICAL; Name: FluMist/B/Victoria; Assigned to Arm(s): FluMist/B/Victoria
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: FluMist | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 1
C: Arm Label: A/H1N1 Vaccine Group 1; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: A/H1N1 Vaccine Group 2; Type: EXPERIMENTAL; Interventions: Biological: Monovalent Subvirion A/H1N1 Influenza vaccine | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Normal saline solution (placebo) | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 1 | Intervention Type: BIOLOGICAL; Name: Monovalent Subvirion A/H1N1 Influenza vaccine; Assigned to Arm(s): A/H1N1 Vaccine Group 2 | Intervention Type: BIOLOGICAL; Name: Normal saline solution (placebo); Assigned to Arm(s): Placebo Group
D: Arm Label: Vaccine; Type: EXPERIMENTAL; Interventions: Biological: SIIL Live Attenuated Influenza Vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: SIIL Live Attenuated Influenza Vaccine; Assigned to Arm(s): Vaccine | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Compare the Safety, Tolerability, Immunogenicity and Efficacy of One Dose and Two Doses of a Liquid Formulation of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) Compared With Placebo in Healthy Children
Brief Summary: The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Biological: FluMist | Intervention Type: BIOLOGICAL; Name: FluMist; Assigned to Arm(s): 1
B: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: EXPERIMENTAL; Interventions: Biological: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: MEDI3414 [Influenza A (H1N1) vaccine]; Type: ACTIVE_COMPARATOR; Interventions: Biological: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal] | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]; Assigned to Arm(s): MEDI3414 [Influenza A (H1N1) vaccine] | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: BIOLOGICAL; Name: CAIV-T; Assigned to Arm(s): N/A

Answer: D